Anbio Biotechnology (NNNN) Fair Value 2026

NNNN · In Vitro & In Vivo Diagnostic Substances ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.3 /10

32 fundamental signals · 13 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-07-15, Anbio Biotechnology (NNNN) trades at $9.12, approximately 222% above CirclFi’s Bayesian DCF fair value of $2.84. QOC: 2.3/10. Value Trap Risk: 12/100 (SAFE). 13/13 models active.

Key Facts

Ticker
NNNN
Price
$9.12
Quality Score
2.3/10
Value Trap Risk
12/100
Models Active
13/13
Last Updated
Strength: First Chicago suggests +275.9% upside with 6% confidence
Risk: Below-average Quality Score of 2.3/10 signals weak fundamentals

Is Anbio Biotechnology (NNNN) Undervalued or Overvalued in 2026?

According to CirclFi’s 13-model valuation engine, Anbio Biotechnology (NNNN) appears overvalued as of : the median of 13 independent fair value estimates is $2.84, 68.9% below the current price of $9.12. Estimates range from $0.21 to $34.28. NNNN scores 2.3/10 on fundamental quality and 12/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Anbio Biotechnology Stock in 2026? →

Valuation Matrix

13 Intrinsic Value Models vs. Current Price ($9.12)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $2.84 -68.9%
Earnings Power Value
Medium Conviction
 $1.40 -84.6%
CUCE Ensemble
Low Conviction
 $5.06 -44.6%
First Chicago
Low Conviction
 $34.28 +275.9%

Unlock the Full Matrix

Access 9 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 13 Models →

Cancel anytime · No contracts · Instant access

What Is Anbio Biotechnology (NNNN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Anbio Biotechnology's intrinsic value is estimated at a composite fair value of $7.07. Trading at $9.12, the stock is approaching fair value or slight overvaluation (implied return of -22.4%), as 9 of 13 models suggest limited further upside. The most optimistic model, First Chicago, places fair value at $34.28 (+275.9%), while Regime Cross — the most conservative — estimates $0.21 (-97.7%). This +373.6% gap reflects genuine analytical uncertainty about Anbio Biotechnology's intrinsic worth.

What Do the Models Say About NNNN?

13 of 13 models are currently active for NNNN. Of these, 4 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates NNNN's intrinsic value at $2.84, implying -68.9% downside from the current price. See which stocks rank higher →

How Does NNNN Rank in In Vitro & In Vivo Diagnostic Substances?

Among 17 In Vitro & In Vivo Diagnostic Substances stocks, NNNN ranks #16 by Quality of Company score. CirclFi's QOC score of 2.3/10 evaluates 32 fundamental signals. A score of 2.3 signals below-average fundamentals.

Anbio Biotechnology operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is NNNN a Value Trap?

CirclFi's Value Trap algorithm assigns NNNN a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

13 of 13 models are active for Anbio Biotechnology. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Anbio Biotechnology earns a quality score of 2.3/10. This concerning rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +373.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NNNN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NNNN's 13 active models, average confidence is 14%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Anbio Biotechnology Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar In Vitro & In Vivo Diagnostic Substances Stocks Should You Also Analyze?

8 related In Vitro & In Vivo Diagnostic Substances stocks with 13-model coverage

IDXXIDEXX Laboratories, Inc.QOC 10.0LNTHLantheus Holdings, Inc.QOC 10.0NEOGNeogen CorporationQOC 7.6ICCCImmuCell CorporationQOC 7.2QDELQuidelOrtho CorporationQOC 6.9NTLAIntellia Therapeutics, Inc.QOC 6.2CLDXCelldex Therapeutics, Inc.QOC 6.1VNRXVolitionRX LimitedQOC 6.1

Read investment analysis: IDXX · LNTH · NEOG · ICCC · QDEL

Frequently Asked Questions About Anbio Biotechnology

What is Anbio Biotechnology's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Anbio Biotechnology (NNNN) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $2.84. The Quality of Company score is 2.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NNNN overvalued or undervalued right now?

At $9.12, 4 of 13 active models suggest NNNN may be undervalued, while 9 indicate potential overvaluation. The median of all 13 fair value estimates is $2.84, 68.9% below the current price of $9.12 — a consensus view that NNNN is overvalued. The assessment depends on which methodology best fits Anbio Biotechnology's business model in In Vitro & In Vivo Diagnostic Substances.

What does a Quality of Company score of 2.3 mean for NNNN?

Anbio Biotechnology's QOC of 2.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on NNNN?

CirclFi analyzes NNNN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 13 of 13 are active for this stock. Read the full methodology →

Is NNNN a value trap in 2026?

Anbio Biotechnology's Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 13-model valuation engine, Anbio Biotechnology (NNNN) has a median fair value of $2.84 — 68.9% below the current price of $9.12 — as of 2026-07-15.” Source: circlfi.com/stock/NNNN/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 13 mathematical frameworks give you clarity on NNNN.

Unlock All 13 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access